Hikma Pharmaceuticals Plc (LON:HIK) has been assigned an average rating of “Buy” from the ten research firms that are currently covering the firm. Three equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is GBX 2,353 ($29.15).

A number of analysts have weighed in on HIK shares. Citigroup Inc. cut Hikma Pharmaceuticals Plc to a “neutral” rating and set a GBX 2,600 ($32.21) price target on the stock. in a research report on Thursday, August 4th. JPMorgan Chase & Co. restated an “overweight” rating and set a GBX 2,550 ($31.59) target price on shares of Hikma Pharmaceuticals Plc in a report on Tuesday, August 16th. Numis Securities Ltd upgraded Hikma Pharmaceuticals Plc to a “buy” rating and set a GBX 2,350 ($29.11) target price on the stock in a report on Friday, November 4th. Morgan Stanley began coverage on Hikma Pharmaceuticals Plc in a report on Thursday, July 21st. They set an “equal weight” rating and a GBX 2,700 ($33.44) target price on the stock. Finally, Barclays PLC restated an “overweight” rating and set a GBX 2,900 ($35.92) target price on shares of Hikma Pharmaceuticals Plc in a report on Friday, September 9th.

In related news, insider Darwazah,Mazen bought 155,991 shares of the business’s stock in a transaction on Tuesday, September 6th. The shares were purchased at an average price of GBX 2,194 ($27.18) per share, with a total value of £3,422,442.54 ($4,239,368.93). Also, insider Al-Husry,Ali bought 140,000 shares of the business’s stock in a transaction on Wednesday, August 31st. The stock was bought at an average cost of GBX 2,150 ($26.63) per share, for a total transaction of £3,010,000 ($3,728,477.64).

Hikma Pharmaceuticals Plc (LON:HIK) opened at 1678.00 on Friday. Hikma Pharmaceuticals Plc has a 52 week low of GBX 1,575.00 and a 52 week high of GBX 2,703.00. The company has a 50-day moving average price of GBX 1,912.41 and a 200-day moving average price of GBX 2,210.27. The stock’s market cap is GBX 3.79 billion.

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.

Receive News & Stock Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related stocks with our FREE daily email newsletter.